Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients

Creative Commons License

Kanbay M. , Siriopol D., Saglam M., Kurt Y. G. , Gok M., Cetinkaya H., et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, cilt.99, 2014 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 99 Konu: 10
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1210/jc.2014-2042
  • Dergi Adı: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Özet

Background: The chronic kidney disease (CKD)-mineral and bone disorder (MBD) syndrome is an important contributor to the CKD-associated cardiovascular disease and high mortality rates. Sclerostin, a protein synthesized in osteocytes, is a potent downregulator of bone metabolism and a novel candidate for the bone-vascular axis in CKD patients. We tested whether serum sclerostin values are predictive for all-cause mortality and cardiovascular events (CVEs) in a CKD population.